NY-MSCI
15.12.2022 15:01:49 CET | Business Wire | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, today announced the launch of MSCI ONE, an open architecture technology platform built on Microsoft Azure that offers global institutional investors an integrated experience to access content across MSCI’s portfolio of products and solutions.
MSCI ONE delivers next-generation capabilities in quantitative investment analytics through a modern, web-based experience that combines flexible distribution, cloud delivery, dashboards, and visualizations. Through this integrated platform, users can seamlessly navigate MSCI’s robust analytics to help them quickly identify key insights, innovate rapidly, gain a broad view of investment risks and opportunities, and build investment portfolios that seek to deliver better strategic outcomes.
Henry Fernandez, Chairman and Chief Executive Officer at MSCI, said: “Today’s investors must synthesize an enormous amount of data to achieve maximum value and power their investment decisions. With MSCI ONE, they will have easy access to a wide range of MSCI tools and solutions, which can help them turn data into insight. This platform represents MSCI’s broader commitment to improving the client experience through transformational technology.”
At launch, MSCI ONE will act as a single point of access for a dozen MSCI services, including MSCI Risk Insights, Climate Solutions (including Climate Lab), and Institutional Client-Designed Indexes with Index Insights. The platform will also host MSCI’s Developer Community and Data Explorer, launched earlier this year. Over time, MSCI ONE will incorporate many more of MSCI’s tools and solutions in a single user experience.
Built on Microsoft Azure, MSCI ONE leverages Microsoft Power BI for live dashboards, interactive reports, charts, graphs, and other visualizations, as well as Azure Cosmos DB and Azure Data Lake for providing insights and data at scale by leveraging key capabilities for data integration, data warehousing, and big data analytics, enabling a seamless and modern experience for MSCI’s clients.
Scott Guthrie, Executive Vice President, Cloud + AI at Microsoft, said: “Microsoft and MSCI share a deep commitment to accelerating innovation. Partnering with Microsoft, MSCI is leveraging cutting-edge innovations in cloud, natural language processing, data distribution and warehousing, and the end-to-end user experience. Whether investors need MSCI’s analytical models, APIs, or user applications, the experiences delivered on MSCI ONE, built on Azure, empower them to choose their approach through an open architecture across MSCI’s portfolio of content and solutions.”
Jigar Thakkar, Chief Technology Officer and Head of Engineering at MSCI, said: “Since the launch of Investment Solutions as a Service in 2021, we have partnered with Microsoft to deliver 10 transformative solutions, culminating in this unique integrated platform MSCI ONE, which will grow to include many of MSCI’s tools and solutions. We have rapidly accelerated the pace of innovation to serve demand for an efficient, open architecture technology platform that allows investors to solve challenges through a customized experience.”
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are in MSCI’s Annual Report on Form 10-K for the most recent fiscal year ended on December 31 that is filed with the SEC. MSCI does not undertake to update any forward-looking statements. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005360/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network26.2.2026 13:04:00 CET | Press release
LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/ Palau National Communications Corporation (PNCC) The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy. PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficie
GoldState Music and Bridgepoint Announce Strategic Partnership Targeting Growth Investments26.2.2026 13:00:00 CET | Press release
Capital will support GoldState Music’s Growth Strategy which will invest in scalable, profitable music-oriented businesses across the music value chainBridgepoint commits a significant investment as lead investor in GoldState’s Growth Strategy Bridgepoint, one of the world’s leading mid-market investors, today announced that it has entered into a strategic partnership with GoldState Music, a premier music investment platform, committing a significant investment as lead investor in GoldState’s Growth Strategy. The capital will support a dedicated investment programme focused on building and scaling high-quality music-oriented businesses globally. GoldState Music is a private investment firm founded in 2022 by industry veteran Charles Goldstuck, who played an integral role in the development of many music enterprises as well as in the careers of numerous major artists and songwriters. The company’s Growth Strategy is focused on investing in and scaling growing businesses operating in the
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics26.2.2026 13:00:00 CET | Press release
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "We anticipate this acquisition will significantly
Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners26.2.2026 13:00:00 CET | Press release
Premium materials, a 12-day battery life and new running features provide support for those kicking off their running journey Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226378156/en/ Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines th
Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery26.2.2026 12:49:00 CET | Press release
The Wyss Center for Bio and Neuroengineering Geneva announced today the successful closing of the Seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick joining existing investors Wyss Center Geneva. Clee Medical spun-out from Wyss Geneva’s Minimally Invasive Intracranial Access (MICA) research project in December 2024. Its flagship platform, Neuro Access, combines OCT imaging with advanced navigation to help neurosurgeons visualize brain anatomy and critical structures in real time during stereotactic procedures. “Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.” Dr. Erwin Böttinger, CEO, Wyss Geneva “Neurosurg
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
